Anji Pharmaceuticals Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

Shanghai China

Primary Industry

Pharmaceuticals

About

Based in Shanghai, China, and established in 2018, Anji Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the R&D of innovative drugs for metabolic diseases. The company's CEO, Ph.D. Brian Hubbard, has over 20 years of biopharmaceutical experience at Millennium Pharmaceuticals, Novartis, and Merck. Also, the company has additional offices in the USA. The company developed candidate drugs for chronic kidney disease and chronic constipation. The company's products pipelines include ANJ900 Metformin DR, ANJ908 Pradigastat, ANJ810 MCL1 Inhibitor and ANJ114 HCK Inhibitor. ANJ900 Metformin DR is designed for gut-targeted delivery of metformin and is in Phase 3 clinical trials for Type 2 diabetes (T2D) patients with moderate renal impairment. ANJ908 Pradigastat is in Phase 2 clinical trials to treat chronic idiopathic constipation. The ANJ810 MCL1 Inhibitor can specific killing cancer cells in preclinical models. ANJ114 HCK Inhibitor can treat myeloid leukemia.

Current Investors

Kaitai Capital, FengHe Fund Management, Wisdomont Capital

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biotechnology, Pharmaceutical Research & Development, Molecular Chemicals, Medicinal Chemicals & Botanicals

Website

www.anjipharma.com

Verticals

HealthTech

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.